Thus, tumor-promoting effects during long-term treatment with NRF2 activators may be a smaller concern when considering long-term treatment of chronic diseases such as NAFLD and NASH with NRF2 activator drugs. Here, NFE2L2 is linked to metabolic dysfunction-associated steatohepatitis.